WaveMan
WaveMan · Company
LUNG · Pulmonx Corp
> Search tickers & screens ⌘K
LIVE
← All companies

LUNG Pulmonx (LUNG) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001127537
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
54
13F, latest reported quarter

What the filings say about LUNG

Insiders, 180 days
-$321.1K net sold
4 sellers · 0% of sales under a 10b5-1 plan

Pulmonx insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Pulmonx Corp insiders sold a net $321.1K of stock across 287 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Lehman David Aaron
General Counsel
SELL
2026-09-03 SECtraded 2026-09-01
3,807
$8.6K
-17.2%
Context
  • 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Jun 1, 2026.
  • The trade is 1.0% of the 372,354 shares held after it.
  • 3 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Lehman David Aaron sold about $8.6K of LUNG on Sep 1, 2026; 3 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Lehman David Aaron
General Counsel
SELL
2026-09-03 SECtraded 2026-09-01
2,224
$5.0K
-17.2%
Context
  • 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Jun 1, 2026.
  • The trade is 0.6% of the 370,130 shares held after it.
  • 3 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Lehman David Aaron sold about $5.0K of LUNG on Sep 1, 2026; 3 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Lehman David Aaron
General Counsel
SELL
2026-09-03 SECtraded 2026-09-01
3,476
$7.9K
-17.2%
Context
  • 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Jun 1, 2026.
  • The trade is 0.9% of the 366,654 shares held after it.
  • 3 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Lehman David Aaron sold about $7.9K of LUNG on Sep 1, 2026; 3 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Lehman David Aaron
General Counsel
SELL
2026-09-03 SECtraded 2026-09-01
4,827
$10.9K
-17.2%
Context
  • 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Jun 1, 2026.
  • The trade is 1.3% of the 361,827 shares held after it.
  • 3 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Lehman David Aaron sold about $10.9K of LUNG on Sep 1, 2026; 3 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Rose Geoffrey Beran
Chief Commercial Officer
SELL
2026-09-03 SECtraded 2026-09-01
2,213
$5.0K
-17.2%
Context
  • 80 earlier Form 4 trades (code P or S) here by this insider (80 sales), the last on Jun 1, 2026.
  • The trade is 0.5% of the 455,498 shares held after it.
  • 3 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Rose Geoffrey Beran sold about $5.0K of LUNG on Sep 1, 2026; 3 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
287 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 282 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$321.1K over 180 days
-$177.0K over 90 days
below 54% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
54 funds bought in last quarter
below 56% of Medical Devices
Revenue
+8.0% year over year
below 56% of Medical Devices
Margin
-59.7% net margin
below 69% of Medical Devices
Buybacks
no share repurchases reported
Short interest
2.1% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
below 66% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LUNG

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+14.4%12M
-27%+3%+33%+62%2025-102025-122026-022026-042026-062026-082026-10 2026-09-01 · French Glendon E. III sold $85.4K2026-03-02 · French Glendon E. III sold $83.5K2026-06-01 · French Glendon E. III sold $59.2K2025-12-08 · Florin Daniel P sold $46.4K2026-06-02 · French Glendon E. III sold $21.2K2026-09-01 · Radhakrishnan Srikanth sold $13.3K2026-09-01 · Lehman David Aaron sold $10.9K2025-12-01 · French Glendon E. III sold $9.9K2026-03-02 · French Glendon E. III sold $9.6K2026-09-01 · French Glendon E. III sold $9.3K2026-06-01 · Radhakrishnan Srikanth sold $9.2K2026-09-01 · Lehman David Aaron sold $8.6K2026-09-01 · Radhakrishnan Srikanth sold $8.2K2026-09-01 · Lehman David Aaron sold $7.9K2026-06-01 · Lehman David Aaron sold $7.6K2026-06-01 · French Glendon E. III sold $6.4K2026-03-02 · Lehman David Aaron sold $6.3K2026-03-02 · Radhakrishnan Srikanth sold $6.0K2026-09-01 · Radhakrishnan Srikanth sold $6.0K2026-06-01 · Lehman David Aaron sold $6.0K2025-12-01 · Lehman David Aaron sold $5.8K2026-03-02 · Lehman David Aaron sold $5.8K2026-06-01 · Radhakrishnan Srikanth sold $5.7K2026-06-01 · Lehman David Aaron sold $5.5K2026-09-01 · Rose Geoffrey Beran sold $5.4K2025-12-01 · Lehman David Aaron sold $5.3K2026-09-01 · Lehman David Aaron sold $5.0K2026-09-01 · Rose Geoffrey Beran sold $5.0K2026-09-01 · Radhakrishnan Srikanth sold $4.8K2026-03-02 · Radhakrishnan Srikanth sold $4.4K2026-03-02 · Rose Geoffrey Beran sold $4.2K2026-06-01 · Radhakrishnan Srikanth sold $4.1K2025-12-01 · French Glendon E. III sold $4.0K2026-09-01 · Rose Geoffrey Beran sold $3.9K2026-03-02 · French Glendon E. III sold $3.9K2026-06-01 · Rose Geoffrey Beran sold $3.7K2025-12-01 · Rose Geoffrey Beran sold $3.7K2026-03-02 · Lehman David Aaron sold $3.7K2026-03-02 · Radhakrishnan Srikanth sold $3.5K2026-06-01 · Lehman David Aaron sold $3.5K2026-06-01 · Rose Geoffrey Beran sold $3.5K2026-09-01 · Rose Geoffrey Beran sold $3.5K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LUNG: institutional holders (13F)

13F holdings, latest reported quarter
PRIMECAP MANAGEMENT CO/CA/
4,612,331 sh
$6.0M
MORGAN STANLEY
2,922,921 sh
$3.8M
Soleus Capital Management, L.P.
2,788,323 sh
$3.6M
Stonepine Capital Management, LLC
1,630,872 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
1,630,219 sh
$2.1M

Congress trades in LUNG

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

LUNG planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LUNG mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
PRIMECAP Odyssey Aggressive Growth Fund
$5.7M position · as of 2026-07-31
0.1%
Ultra-Small Company Market Fund
$79.3K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$178.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.2K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$59.9K position · as of 2026-05-31
0.0%
Guardian Large Cap Fundamental Growth VIP Fund
$4.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $321.1K sold by insiders over 180 days, 54 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

LUNG financials

Revenue growth
+8.0%
XBRL, annual
Net margin
-59.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$87.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-55.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$30.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.96x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-0.81x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-88.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-36.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-42.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$60.3M
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-39.0%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$90.5M$83.8M$68.7M$53.7M
Gross profit$67.1M$62.0M$50.8M$39.9M
Operating income-$53.7M-$57.7M-$61.9M-$58.6M
Net income-$54.0M-$56.4M-$60.8M-$58.9M
EPS (diluted)-1.33-1.44-1.60-1.59
Operating cash flow-$32.4M-$31.5M-$37.6M-$45.1M
Cash$69.8M$70.9M$83.5M$101.7M
Long-term debt$37.0M$34.0M$35.1M$17.2M
Buybacksn/an/a$0$27.0K
SEC XBRL, fiscal years, as known on 2026-10-27

LUNG Stock Sonar score 6/7 axes

Find similar shapesCompare

LUNG ranks highest on risk and compliance (54th percentile) and growth (44th), and lowest on insider conviction (23rd), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
33
Inputs
  • Return on equity-88.9% · 28 pct, sector of 183
  • Return on assets-36.7% · 36 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-42.3% · 35 pct, sector of 188
Financial health
27
Inputs
  • Debt to equity0.96x · 20 pct, sector of 159
  • Cash flow to debt-0.81x · 34 pct, sector of 150
Growth
44
Inputs
  • Revenue growth, YoY+8.0% · 44 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
23
Inputs
  • Net Form 4 buying (codes P and S), 180d-$321K · 45 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
44
Inputs
  • Funds adding, latest quarter54 · 44 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+2.1% · 71 pct, sector of 240
  • Recalls per $1B revenue, 3y11.05 per $1B · 12 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+5.8% · 78 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LUNG filings, in plain words

Are Pulmonx insiders buying or selling LUNG?

In the 180 days to 2026-10-27, Pulmonx insiders were net sellers, a net $321.1K across purchases and sales reported on Form 4, by 4 sellers.

Read the full summary

In the 180 days to 2026-10-27, Pulmonx insiders were net sellers of LUNG, a net $321.1K across purchases and sales reported on Form 4 by 4 sellers. None of the 29 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies